Sort   by:  
 Page size 
UnknownIntegrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Not available
S-EPMC9153017 | biostudies-literature
UnknownOutcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Not available
S-EPMC7552812 | biostudies-literature
UnknownOutcomes of COVID-19 in patients with CLL: a multicenter international experience.
Not available
S-EPMC7472711 | biostudies-literature
UnknownTumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
Not available
S-EPMC8020996 | biostudies-literature
UnknownReal-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Not available
S-EPMC6119152 | biostudies-literature
UnknownCOVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Not available
S-EPMC8313815 | biostudies-literature
UnknownFine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk.
Not available
S-EPMC4321445 | biostudies-literature
UnknownEmpagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483 | biostudies-literature
UnknownHigher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607 | biostudies-literature
UnknownBaricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Not available
S-EPMC9333998 | biostudies-literature
Sort   by:  
 Page size